Citations

Clear

2117 citation(s) found for "Mayo, Steven".

Atrial Fibrillation After Surgical Correction of Mitral Regurgitation in Sinus Rhythm
Kernis, Steven J., Messika–Zeitoun, David , Sundt, Thoralf M. , Scott, Christopher G. , Schaff, Hartzell V. , Nkomo, Vuyisile T. , Gersh, Bernard J. , Ballman, Karla V. , Enriquez‐Sarano, Maurice , Scott, Christopher , Enriquez-Sarano, Maurice , Schaff, Hartzell , Messika-Zeitoun, David

Mayo Clinic

Circulation | October 12, 2004 | Volume: 110 | Issue: 16 | Pages: 2320-2325

10.1161/01.cir.0000145121.25259.54 | PMID 15477410 Get It

Background— The incidence, determinants, and outcome of postoperative atrial fibrillation (AF) after surgery for mitral regurgitation (MR) are poorly defined but may have important implications for timing of mitral valve surgery. Methods and Results— In 762 patients in sinus rhythm with no AF history undergoing MR surgical correction, we examined the rates and prognostic implications of postoperative AF for early AF (within 2 weeks postoperatively) and late AF (>2 weeks after surgery). During postoperative follow-up, 180 patients (24%) experienced new AF (early AF in 136 and late AF in 111). Isolated early AF without recurrence was observed in 69 patients characterized by high angina class and lower left ventricular ejection fraction but no significant left atrial (LA) enlargement. However, overall early AF predicted late AF: 62±5% of patients with early AF had late AF at 10 years compared with 9±1% of patients without early AF ( P <0.0001). Large LA size strongly and independently predicted early AF ( P =0.01) and late AF ( P =0.003). For late AF, the predictive value of an enlarged LA was cumulative to that of early AF. Postoperative AF was associated with an increased subsequently higher risk of stroke or congestive heart failure (adjusted risk ratio=1.46 [1.04 to 2.05], P =0.03). Conclusions— Postoperative AF is common after surgical correction of MR in patients with no prior history of AF and is associated with increased subsequent morbidity. LA enlargement is independently predictive of postoperative AF and as such, should be integrated into the clinical decision-making process in patients with MR.
Cathepsin B inactivation attenuates hepatocyte apoptosis and liver damage in steatotic livers after cold ischemia-warm reperfusion injury
Baskin-Bey, Edwina, Canbay, Ali , Bronk, Steven F., Werneburg, Nathan W., Guicciardi, Maria Eugenia , Nyberg, Scott L. , Gores, Gregory J. , Canbay, Ali

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | October 7, 2004 | Volume: 288 | Issue: 2 | Pages: G396-G402

10.1152/ajpgi.00316.2004 | PMID 15472011 Get It

Hepatic steatosis predisposes the liver to cold ischemia-warm reperfusion (CI/WR) injury by unclear mechanisms. Because hepatic steatosis has recently been associated with a lysosomal pathway of apoptosis, our aim was to determine whether this cell-death pathway contributes to CI/WR injury of steatotic livers. Wild-type and cathepsin B-knockout ( Ctsb −/−) mice were fed the methionine/choline-deficient (MCD) diet for 2 wk to induce hepatic steatosis. Mouse livers were stored in the University of Wisconsin solution for 24 h at 4°C and reperfused for 1 h at 37°C in vitro. Immunofluorescence analysis of the lysosomal enzymes cathepsin B and D showed a punctated intracellular pattern consistent with lysosomal localization in wild-type mice fed a standard diet after CI/WR injury. In contrast, cathepsin B and D fluorescence became diffuse in livers from wild-type mice fed MCD diet after CI/WR, indicating that lysosomal permeabilization had occurred. Hepatocyte apoptosis was rare in both normal and steatotic livers in the absence of CI/WR injury but increased in wild-type mice fed an MCD diet and subjected to CI/WR injury. In contrast, hepatocyte apoptosis and liver damage were reduced in Ctsb −/− and cathepsin B inhibitor-treated mice fed the MCD diet following CI/WR injury. In conclusion, these findings support a prominent role for the lysosomal pathway of apoptosis in steatotic livers following CI/WR injury.
Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy
Silberstein, Peter T., Loprinzi, Charles L. , Sloan, Jeff A. , Novotny, Paul J. , Mailliard, James A., Rowland, Kendrith M. , Krook, James E., Levitt, Ralph, Morton, Roscoe F., Witzig, Thomas E. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | September 28, 2004 | Volume: 23 | Issue: 12 | Pages: 2606-2617

10.1200/jco.2004.10.020 | PMID 15452187 Get It

Purpose To determine whether weekly epoetin alfa could improve hemoglobin (HgB) levels, reduce RBC transfusions, and improve quality of life (QOL) in patients with advanced cancer and with anemia after receiving myelosuppressive chemotherapy. Patients and Methods This double-blind, placebo-controlled study randomly assigned patients to placebo or epoetin alfa (Ortho Biotech, Bridgewater, NJ) 40,000 U subcutaneous weekly for 16 weeks. QOL, HgB, and RBC transfusions were measured pretreatment and monthly. Results The study accrued 344 patients; 330 were assessable for efficacy and 305 were assessable for QOL. Placebo-treated patients had a mean increase in HgB of 0.9 g/dL (range, −3.8 to +5.3) compared with 2.8 g/dL (range, −2.2 to +7.5) for epoetin-treated patients (P < .0001). During the study, 31.7% of placebo-treated patients achieved a ≥ 2 g/dL HgB increase compared with 72.7% of epoetin-treated patients (P < .0001). The incidence of RBC transfusion for placebo and epoetin treatment arms was 39.6% and 25.3% (P = .005), respectively. The placebo group received 256 units of RBCs compared with 127 units in the epoetin group (P < .0001). The incidence of toxicity in the groups was similar. Changes in the average QOL scores from baseline to the end of the study were similar in the two groups (P = not significant). The HgB responders (irrespective of treatment arm) had a mean change in Functional Assessment of Cancer Therapy (FACT) fatigue score from a baseline of +5.1 compared with −2.1 for the nonresponders (P = .006). Conclusion Epoetin alfa significantly improved HgB and reduced transfusions in this patient population. These results support the use of weekly epoetin alfa as an ameliorative agent for cancer-related anemia.
Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
Dispenzieri, Angela , Kyle, Robert A. , Lacy, Martha Q. , Burritt, Mary F., Therneau, Terry M. , Greipp, Philip R., Lust, John A., Rajkumar, S. Vincent , Fonseca, Rafaël , Zeldenrust, Steven R., McGregor, Christopher G.A. , Jaffe, Allan S. , Gertz, Morie A. , Witzig, Thomas E. , Jaffe, Allan S. , Rajkumar, S Vincent , Dispenzieri, Angela , Fonseca, Rafael

Mayo Clinic

Journal of Clinical Oncology | September 13, 2004 | Volume: 22 | Issue: 18 | Pages: 3751-3757

10.1200/jco.2004.03.029 | PMID 15365071 Get It

Purpose Primary systemic amyloidosis (AL) is a multisystemic disorder resulting from an underlying plasma cell dyscrasia. There is no formal staging system for AL, making comparisons between studies and treatment centers difficult. Our group previously identified elevated serum cardiac troponin T (cTnT) as the most powerful predictor of overall survival. Others have reported that N-terminal pro-brain natriuretic peptide (NT-proBNP) is a valuable prognostic marker. We sought to develop a staging system for patients with AL. Patients and Methods Two hundred forty-two patients with newly diagnosed AL who were seen at the Mayo Clinic between April 1979 and November 2000, and who had echocardiograms and stored serum samples at presentation were eligible for this retrospective review. NT-proBNP measurements were performed on 242 patients in whom cTnT and cardiac troponin I (cTnI) had been previously run. Two prognostic models were designed using threshold values of NT-proBNP and either cTnT or cTnI (NT-proBNP < 332 ng/L, cTnT < 0.035 μg/L, and cTnI < 0.1 μg/L). Depending on whether NT-proBNP and troponin levels were both low, were high for only one level, or were both high, patients were classified as stage I, II, or III, respectively. Results Using the cTnT+NT-proBNP model 33%, 30%, and 37% of patients were stages I, II, and III, respectively, with median survivals of 26.4, 10.5, and 3.5 months, respectively. The alternate cTnI+NT-proBNP model predicted median survivals of 27.2, 11.1, and 4.1 months, respectively. Conclusion Stratification of AL patients into three stages is possible with two readily available and reproducible tests setting the stage for more consistent and reliable cross comparisons of therapeutic outcomes.
Low Agreement Between Previous Physician Diagnosed Prostatitis and National Institutes of Health Chronic Prostatitis Symptom Index Pain Measures
Roberts, Rosebud O., Jacobson, Debra J., Rhodes, Thomas , Lieber, Michael M., Jacobsen, Steven J. , Girman, Cynthia J.

Mayo Clinic

Journal of Urology | August 25, 2004 | Volume: 171 | Issue: 1 | Pages: 279-283

10.1097/01.ju.0000100088.70887.29 | PMID 14665894 Get It

RE: EFFECT OF NONSTEROIDAL ANTI-INFLAMMATORY AGENTS AND FINASTERIDE ON PROSTATE CANCER RISK
Jacobsen, Steven J. , Roberts, Rosebud O.

Mayo Clinic

Journal of Urology | August 25, 2004 | Volume: 169 | Issue: 5 | Pages: 1798-1799

10.1097/01.ju.0000057804.01025.13 | PMID 12686844 Get It

Radiotherapy for Men With Isolated Increase in Serum Prostate Specific Antigen After Radical Prostatectomy
Macdonald, O. Kenneth, Schild, Steven E. , Vora, Sujay A., Andrews, Paul E. , Ferrigni, Robert G., Novicki, Donald E., Swanson, Scott K., Wong, William W. , Schild, Steven

Mayo Clinic

Journal of Urology | August 25, 2004 | Volume: 170 | Issue: 5 | Pages: 1833-1837

10.1097/01.ju.0000091835.80547.a4 | PMID 14532786 Get It

Heart Failure after Myocardial Infarction: Clinical Presentation and Survival
Hellermann, Jens, Jacobsen, Steven J. , Redfield, Margaret M. , Reeder, Guy S., Weston, Susan A., Roger, Véronique L.

Mayo Clinic

European Journal of Heart Failure | August 24, 2004 | Volume: 7 | Issue: 1 | Pages: 119-125

10.1016/j.ejheart.2004.04.011 | PMID 15642543 Get It

Abstract Objectives To characterize the presentation and outcome of patients with heart failure (HF) after myocardial infarction (MI) according to left ventricular ejection fraction (LVEF) and test the hypothesis that the outcome of HF did not change over time. Background Little is known about the presentation and outcome of HF post-MI and how these may have changed over time. Methods Using the Rochester Epidemiology Project, all residents of Olmsted County, Minnesota who experienced an incident MI between 1979 and 1998 were identified; MI and HF were validated using standardized criteria. Subjects were followed through their community medical record. Results Between 1979 and 1998, 1915 patients with incident MI and no prior history of HF were identified. Of these, 791(41%) experienced new onset HF as defined by Framingham criteria during 6.6±5.0 years of follow-up. Forty-seven percent were men, mean age was 73±12 years. Forty-four percent had impaired LVEF, 18% preserved LVEF and 38% had no LVEF measurement within 60 days after the HF event. Median survival after HF onset was 4 years and at 5 years after HF onset, only 45% were alive. Older age, male sex, comorbidity, hypertension and no LVEF assessment were associated with increased risk of death, however, patients with impaired LVEF had the worst outcome. Over time, survival did not improve (HR for year: 1.00; 95% CI 0.99, 1.02; P=0.919) even after adjustment for baseline characteristics. Conclusion In this geographically defined cohort of patients with MI, new onset HF after the MI was frequent. When measured, LVEF was most frequently reduced, consistent with systolic heart failure. Mortality was high and did not decline over time and death was independently associated with male sex, older age, hypertension and comorbidity. It also differed according to LVEF, which was inconsistently ascertained in this setting, potentially representing practice opportunities.
Malignant Pineal Parenchymal Tumors in Adult Patients: Patterns of Care and Prognostic Factors
Lutterbach, Johannes, Fauchon, F., Schild, Steven E. , Chang, Susan M. , Pagenstecher, Axel , Volk, Benedikt, Ostertag, Christoph B., Momm, Felix , Jouvet, Anne, Schild, Steven

Mayo Clinic

Neurosurgery | July 29, 2004 | Volume: 51 | Issue: 1 | Pages: 44-56

10.1097/00006123-200207000-00006 | PMID 12182434 Get It

Abstract OBJECTIVE The aim of our study was to analyze patterns of care and to identify prognostic factors in patients at least 18 years of age who received radiotherapy for malignant pineal parenchymal tumors. METHODS In a multicenter, retrospective study, we analyzed data for 37 previously published cases and 64 patients treated at the participating institutions. RESULTS A total of 56 patients received postoperative radiotherapy, and 45 patients received primary radiotherapy. Chemotherapy was administered to 34 patients. The median follow-up period was 38 months, and median overall survival was 100 months. The variables that significantly influenced overall survival were the extent of disease (localized versus disseminated; P = 0.0002), differentiation (pineal parenchymal tumor of intermediate differentiation versus pineoblastoma; P = 0.001), and residual disease (≥50% versus &lt;50% reduction in size; P &lt; 0.0001). In a multivariate analysis, the parameters turned out to be independent risk factors. The median survival in patients with local or spinal failure was 15 months. Local control was better in older patients (≥32 yr versus &lt;32 yr; P = 0.02). Spinal control was more successful in patients with pineal parenchymal tumors of intermediate differentiation than it was in patients with pineoblastomas (P = 0.03). Nine of 45 treatment failures occurred later than 5 years after treatment. CONCLUSION Stage, histological characteristics, and response are independent risk factors in adults with malignant pineal parenchymal tumors. Late relapses are common.
Critical evaluation of the different staging systems for hepatocellular carcinoma (Br J Surg 2004; 91: 400-408)
Pawlik, Timothy M. , Lauwers, Gregory Y. , Nagorney, David M. , Curley, Steven A. , Poon, Ronnie T.P., Belghiti, Jacques, Greene, Frederick L. , Henderson, J. Michael, Vauthey, Jean‐Nicolas , Roh, Mark S.

Mayo Clinic

British Journal of Surgery | July 27, 2004 | Volume: 91 | Issue: 8 | Pages: 1072-1072

10.1002/bjs.4782 | PMID 15286973 Get It

Abstract The Editors welcome topical correspondence from readers relating to articles published in the Journal. Responses can be sent electronically via the BJS website (www.bjs.co.uk) or by post. All letters will be reviewed and, if approved, appear on the website. A selection of these will be edited and published in the Journal. Letters must be no more than 250 words in length. Letters submitted by post should be typed on A4-sized paper in double spacing and should be accompanied by a disk.